logo

For the Inventor, By the Inventor

Cranbury, NJ, United States of America

Amicus Therapeutics, Inc.


USPTO Granted Patents = 161

% Expired Patents = 4.3



Trademarks = 17

Forward Citations = 2,002

Loading Chart...
Loading Chart...

56 inventors (with patents filed for the assignee):

goldMedal Jeff Castelli (58 out of 59 patents)

silverMedal Elfrida Benjamin (56 out of 56 patents)

bronzeMedal Hung V Do (33 out of 33 patents)

4.  Robert E Boyd (20 out of 33 patents)

5.  Russell Gotschall (17 out of 17 patents)

6.  Brandon Alan Wustman (15 out of 19 patents)

7.  David J Lockhart (15 out of 61 patents)

8.  Richie Khanna (14 out of 14 patents)

9.  Gary Lee (14 out of 15 patents)

10.  Kenneth Valenzano (13 out of 13 patents)

11.  Philip J Rybczynski (12 out of 32 patents)

12.  Kamlesh A Sheth (12 out of 12 patents)

13.  John R Flanagan (11 out of 139 patents)

14.  Sergey Tesler (8 out of 8 patents)

15.  John Crowley (6 out of 6 patents)


Core Competencies:
Lysosomal Storage Diseases
Fabry Disease
Pompe Disease
Pharmacological Chaperones
Acid Alpha-Glucosidase
Recombinant Proteins
Gene Therapy Constructs
Degenerative Disorders
Migalastat
Disulfide Bond Stabilized Polypeptides
Alzheimer's Disease

161 patents:

1. 12686859 - Method For Selection Of High M6P Recombinant Proteins (2026-07-21),
2. 12622952 - FORMULATIONS COMPRISING RECOMBINANT ACID ALPHA-GLUCOSIDASE (2026-05-12),
3. 12599595 - Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones (2026-04-14),
4. 12552736 - Compositions for preventing and/or treating degenerative disorders of the central nervous system and/or lysosomal storage disorders (2026-02-17),
5. 12419937 - High concentration alpha-glucosidase compositions for the treatment of Pompe disease (2025-09-23),
6. 12414985 - Augmented acid alpha-glucosidase for the treatment of Pompe disease (2025-09-16),
7. 12414944 - Methods of treating fabry disease in patients having the G9331A mutation in the GLA gene (2025-09-16),
8. D1087752 - Drug package (2025-08-12),
9. D1082532 - Drug package (2025-07-08),
10. 12280042 - Methods of treating fabry patients having renal impairment (2025-04-21),
11. 12275703 - Highly purified batches of pharmaceutical grade migalastat and methods of producing the same (2025-04-14),
12. 12246062 - Recombinant human acid alpha-glucosidase (2025-03-11),
13. 12109205 - Methods of treating Fabry patients having renal impairment (2024-10-08),
14. 12070453 - Treatment of Fabry disease in ERT-naïve and ERT-experienced patients (2024-08-27),
15. 12064485 - Disulfide bond stabilized polypeptide compositions and methods of use (2024-08-20),
Amicus Therapeutics, Inc. is a global biotechnology company focused on discovering, developing, and delivering novel medicines for people living with rare diseases. With a patient-centric approach, Amicus aims to develop innovative therapies to address significant unmet medical needs. The company's research and development efforts are directed towards a range of genetic diseases, including lysosomal storage disorders and muscular dystrophies. Amicus is committed to potentially transforming the lives of patients and their families through pioneering treatments.
This text is generated by artificial intelligence and may not be accurate.

logo

Company Badge

USPTO Data Jan 1 1976 - Sep 15 2026

Amicus Therapeutics, Inc.
161 Patents

#2 in Cranbury, NJ

#114 in New Jersey

#2,462 in US

#5,108 in the World

Cranbury, NJ (US)
Cranbury, NJ, United States of America

Amicus Therapeutics, Inc.

Forward Citations = 2,002

56 inventors:

goldMedal Jeff Castelli (58 out of 59 patents)

silverMedal Elfrida Benjamin (56 out of 56 patents)

bronzeMedal Hung V Do (33 out of 33 patents)

4.  Robert E Boyd (20 out of 33 patents)

5.  Russell Gotschall (17 out of 17 patents)

Please report any incorrect information to [email protected]
Loading…